key: cord-0287638-qvk4gwk6 authors: Lewandowska, M.; Carter, D. J.; Lohr, P. A.; Wellings, K. title: Examining impacts of approval of home use of misoprostol in England on access to medical abortion date: 2022-03-31 journal: nan DOI: 10.1101/2022.03.28.22273043 sha: 6e63e96fa5dae319c1d3bce07d46eeb8d7bec741 doc_id: 287638 cord_uid: qvk4gwk6 Objectives To assess the impact of the December 2018 approval of home administration of misoprostol in England on access to medical abortion. Design Time series analysis Setting British Pregnancy Advisory Service (BPAS), independent-sector abortion provider in England Participants 145,529 abortions carried out by BPAS across England between 2018 and 2019. Intervention Approval of home administration of misoprostol in early medical abortions (EMA) in December 2018 Main outcome measure Gestational age at abortion and EMAs as a proportion of all abortions. The analysis was stratified by key sociodemographic characteristics to assess differential impacts of the approval Results 99,008 abortions took place in the period before the approval or during its implementation phase (January 2018 - June 2019) and 46,521 took place after (July 2019 - Dec 2019). Compared to if former trends had continued, the actual proportion of EMAs was 4.2% higher in December 2019 and the mean gestational age 3.4 days lower. Conclusion Following the approval of home use of misoprostol, we saw an acceleration in the trends towards increasing proportion of all abortions that were EMAs and decreasing gestational age at abortion, especially in more deprived areas of England. Some inequities remain across race/ethnicity groups that require further investigation. Policymakers should take the positive results of this study into consideration when reviewing rules for home management of medical abortions, including with home use of mifepristone. What is already known on this topic In 2018 in England, a woman's "home" was designated as a class of place where misoprostol could be used to induce abortion up to 10 weeks' gestation following administration of mifepristone in a medical facility. This model of abortion care has been shown in numerous international studies to be highly effective, safe, and preferred by women over in-clinic use. Existing data anticipated positive clinical and acceptability outcomes with implementation of home use, but whether or how the change would impact access particularly in relation to barriers such as area-level deprivation, race/ethnicity, and disability was uncertain. The approval of home use of misoprostol as part of a medical abortion regimen in England was associated with material and equitable improvements in abortion access as evidenced by a higher proportion of medical abortions provided, lower gestational age at treatment, and higher odds of having a medical abortion across all racial/ethnic groups and socioeconomic groups. Pre-approval trends toward greater uptake of medical abortion and declining gestational age were accelerated post-approval and were greatest in the most deprived quintiles but not across all racial/ethnic groups. This study was a quantitative data analysis of existing clinical data and patients were not directly involved in the research. 3 Background Medical abortion involves the administration of mifepristone, followed 24-48 hours later by misoprostol, resulting in loss of the pregnancy in a process similar to miscarriage. ( Early medical abortion (EMA) refers to the use of mifepristone and misoprostol in the first 10-12 weeks of pregnancy. In many parts of the world, self-administration of misoprostol at home has been the standard model of care, in line with evidence demonstrating it to be safe, effective, and acceptable. (6, 7) Until 2017, those seeking EMA in Britain were legally required to attend an approved clinic or NHS hospital to have these medications administered. (8, 9) In almost all cases, the patients would not remain in the clinical setting after receiving the medications but would return home to complete the abortion. Home administration of medical abortion has been repeatedly proposed in the early stages of pregnancy as a means of improving access to care and mitigating psychological, financial, and logistical burdens. It has several advantages: it allows for increased privacy, affords opportunities for support from family and friends and provides greater comfort. (10-13) The alternative -travelling home after administration of misoprostol in a clinical setting -increases travel time and associated expenses, can incur income loss, and carries the risk of causing distress in the event of onset of bleeding and pain during the journey. (3, 10, (13) (14) (15) (16) Increasing access to medical abortion can also result in abortions being provided earlier in pregnancy by mechanisms including both increased provider capacity and improved patient experience. While abortion is a very safe procedure overall, the risk of potential complications increases with every subsequent week of gestation. (1) Earlier abortions minimise the risk of adverse events and improve women's experience of abortion care. There is also strong evidence that earlier abortions are more cost-effective for health systems: the savings a All rights reserved. No reuse allowed without permission. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in (1, 17, 18) In December 2018, the Secretary of State for Health in England approved "home" as a place where misoprostol as part of medical abortion regimen could lawfully be administered. This measure, conforming with the World Health Organization (WHO) guidelines, (19) brought England in line with Wales, where home use had been approved in June 2018, and with Scotland, where it was approved in October 2017. (20) The approval of home use in England and Wales is limited to early medical abortions (EMA), defined as under 10 weeks' gestation. In 2019, 36% of medical abortions in England and Wales were carried out with misoprostol administered at home. (5) In this study, we examined the impacts of the December 2018 ruling permitting home administration of misoprostol. We analysed routinely collected data on abortion to explore changes in the proportion of all abortions carried out by EMA, and in the gestational age at which abortions were carried out, before and after the ruling. We also examined whether any such changes varied by key population characteristics related to inequality, to understand effects by area-level deprivation, race/ethnicity, and disability. All rights reserved. No reuse allowed without permission. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in Figure S1 ). We therefore restricted our analysis to the time when the increase in this proportion was linear and stationary: from January 2018 to December 2019. We asked whether the approval permitting home administration of misoprostol was associated with a change in the ratio of EMAs to late medical or surgical abortions, in gestational age at treatment, and whether any observed changes varied with patient characteristics. We used the restricted sample from January 2018 to December 2019 and described it in terms of abortion method, gestational age, past experience of abortion and distribution of demographic characteristics. In this paper, we use the term EMA as under 10 weeks' gestation. Since whether the impacts of the approval on access to care vary in line with social inequities is of considerable public health interest, we conducted three further stratified analyses to examine differential effects by area-level deprivation, race/ethnicity, and disability. Deprivation was derived from the first three letters of patients' postcode linked to We conducted a Mantel-Haenszel analysis to compare the prevalence of EMA in the period before and after the approval, stratified by patient subgroups, and reported proportions and crude odds ratios (ORs). We also conducted a univariable linear regression to provide mean gestational age at abortion, stratified by patient characteristics, and the risk difference prepost the approval. We then conducted an interrupted time series analysis (ITS) using segmented linear regression analyses. We examined the slope of fitted regression lines that represent the expected increase or decrease in gestational age or proportion of EMAs for each additional month in time. We specifically estimated the expected change in these slopes after the implementation of the new care model, anticipating an effect of the approval on the rate of change in our outcomes of interest. Given full implementation of the exposure was not achieved until approximately 6 months after the approval (see Figure S2 ), we include a 6month transition period post-legislation as part of the pre-implementation period. Effect modification by social categories (deprivation, race/ethnicity, disability) was tested by introducing a three-way interaction term into the model to test the null hypothesis that the slope change post-approval was the same in each group. A Durbin-Watson test was conducted, and visual plots of autocorrelation functions were produced to examine whether the ITS assumption that each observation is not dependent on previous observations holds. Change in slopes expected across the time period were plotted graphically. We also estimated average differences in outcome at the endpoint of December 2019 by comparing the observed outcomes to a counterfactual in the absence of intervention, that is, assuming that there was no slope change. All analyses presented in this paper were conducted in R v4.1.2 and the code is available post-publication at http://github.com/danieljcarter/bpas. All rights reserved. No reuse allowed without permission. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in Between January 2018 and December 2019, 145,548 abortions were conducted by BPAS, of which 102,592 (70.5%) were EMAs. The gestational age at abortion ranged from 21 days (3 weeks) to 168 days (24 weeks), with a median of 52 days (7 weeks and 3 days), and a mean of 59 days, rounded to the nearest whole number. The characteristics of the sample are provided in Table 1 . Following the approval and implementation of home misoprostol, EMA as a proportion of all abortions carried out by BPAS increased from 69.8% to 72.0% [1.12 (1.09, 1.14)] (Table 2a) . We also saw a decrease in mean gestation for patients undergoing late medical and surgical abortions: from 82.6 to 77.63 days [-4.95 (-5.31, -4.59)]. Significant decreases were seen across all but the oldest age group; and across all birth places except Wales, Scotland and Northern Ireland. The decrease was more marked among non-White patients; among those of non-Christian religious affiliation; and among those who had previously had an abortion. All rights reserved. No reuse allowed without permission. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in The estimated slope changes from the stratified time series analyses are presented in Table 3 . We found some evidence that the change in slope post-approval differed by levels of raceethnicity, and by levels of disability for both outcomes, and some weak evidence for difference by IMD. The magnitude of the slope change post-implementation in the proportion of individuals having EMAs and in gestational age generally increased going from least to most deprived. In terms of ethnicity, all groups demonstrated weak evidence of a slope change post-approval on either the EMA measure or the gestational age measure except for Black or Black British women. The largest predicted accelerations in the decrease in gestational age post-approval were seen in Asian or Asian British and White women. Post-approval, the slope change in people with disabilities was faster than in those without disabilities. Figures 2a, 2b, and 2c present illustrative differences in EMAs by IMD, race/ethnicity, and disability. All rights reserved. No reuse allowed without permission. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in We found that access to EMA improved after the approval of home misoprostol, as evidenced by the higher proportion of EMAs provided, lower gestational age at treatment, and higher odds of having an EMA across almost all ethnic groups and socioeconomic groups. The only group that did not experience an increase in the odds of having EMA was those born in Northern Ireland. Already prior to the approval for home use of misoprostol in England as part of an EMA regimen, the proportion of abortions performed medically at BPAS was on the rise and gestational age at treatment was declining, but we found that these trends were accelerated. These accelerations were larger in the most deprived quintiles and in those reporting a disability, but not equal across ethnic groups, with Black and Black British women experiencing little change in trajectories post-approval. A strength of the study was that it was a unique opportunity to assess the impact of the 2018 approval of home use of misoprostol prior to the COVID-19 pandemic, when medical abortion became the default method in the first 10 weeks of pregnancy. (25) The study sample was large, constituting 35.67% of all 407,992 abortions carried out in England and Wales between 2018 and 2019. (5,21,26) It was also representative, including a wide range of age groups, ethnicities, religions, and national origins. There is some potential source of selection bias resulting from the fact that we used data from only one clinical provider and so were unable to account for clinic-based differences in the speed of implementation or factors favouring a certain method of abortion. A limitation of the analysis is that the comparator data collection period following the ruling was short, only six months, which may have resulted in an underestimate of eventual changes. The trends would likely have been stronger had there been more time points to analyse. Any extension of this period beyond March 2020, however, would have been confounded by the changes in abortion regulations contingent on the COVID-19 pandemic that were introduced in April 2020. All rights reserved. No reuse allowed without permission. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in Our finding that the approval of home use of misoprostol was associated with an acceleration of existing trends in lower gestational age at treatment is important because it means more people in Britain can access EMA at home: it facilitates abortions taking place under the upper gestational age limit imposed by law and it can alleviate the distress caused by longer waiting times to abortion. In addition, the earlier in pregnancy abortions take place, the safer and more effective they are. (1, 17) The concomitant acceleration in trend toward more EMAs also has cost implications: EMA is less expensive to provide than surgical abortion, and earlier abortions are associated with a reduction in the need for costly surgical management of complications such as incomplete abortion and continuing pregnancy. (18) NICE estimates that in England a reduction of one day in gestational age at abortion could save £1.6 million per year -our findings that the approval of home use of misoprostol facilitated abortions happening over three days earlier show a significant economic potential of the change. (1, 27) At-home administration of misoprostol can particularly improve access to abortion in more deprived areas, for people with disabilities, and in some ethnic groups, as those populations can suffer from barriers to access, such as issues with travel, taking time off work and arranging childcare, significantly more. Home administration showed little evidence of improving access to abortion in Black and Black British women and further research should be conducted to understand this difference in uptake to better tailor abortion care services to reach marginalised populations. There are other limitations to the DHSC's approval. Firstly, the narrow definition of "home" might restrict access to some and doesn't account for people for whom that location may be undesirable on grounds of safety. (27-29) Secondly, the arbitrary cut-off of 9+6 weeks, which is not reflected in literature, and studies have provided no evidence that home expulsion between 10 and 12 weeks is less effective, less acceptable, or less safe. (1, 27, 30, 31) Since the approval of home use of misoprostol, the COVID-19 pandemic impelled a sudden and rapid shift towards the telemedical model and the home management of the whole All rights reserved. No reuse allowed without permission. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in The copyright holder for this this version posted March 31, 2022. ; https://doi.org/10.1101/2022.03.28.22273043 doi: medRxiv preprint medical abortion process. There is accumulating evidence that, much like with misoprostol, home administration of mifepristone is also safe, effective, and preferred by women. (1, 27, 30, 31) This swift move towards remote care resulted in further improvements in access: data from BPAS from March to June 2020 showed that waiting times for appointments halved, with an average of 4 days, and that average gestation fell by over 7 days, comparing the first half of 2019 to that of 2020. (32) The impact of this change on indices such as area-level deprivation, race/ethnicity, and disability is an area for further exploration. In addition, it is essential to continue exploring patients' perspectives of those new models of care. In a qualitative study conducted in England during the COVID-19 pandemic, we found that women were overwhelmingly in favour of home self-management of medical abortion, but some stressed that the option of an in-person interaction with health practitioners should remain available. (33) Another study indicated that some women expressed concerns about whether the symptoms were experiencing during home termination were "normal". (29) Greater autonomy in the management of EMA by women themselves has demonstrable clinical and experiential benefits and appears to have the potential to improve access by those who often face the greatest barriers to abortion care. The measures allowing for the home administration of mifepristone were approved on a temporary basis, and are currently set to end in August 2022, despite the abundance of evidence showing it to be a more accessible and acceptable model. Our research shows that remote care has a great potential in improving access and equity of abortion care in the country. All rights reserved. No reuse allowed without permission. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in The copyright holder for this this version posted March 31, 2022. ; https://doi.org/10.1101/2022.03.28.22273043 doi: medRxiv preprint Abortion Care. 2020. 2. Office for National Statistics. Abortion statistics Clinical Guidelines for Early Medical Abortion at Home-England Rationale and Scope Effectiveness, safety and acceptability of medical abortion at home versus in the clinic: A systematic review and meta-analysis in response to COVID-19 Comparative effectiveness, safety and acceptability of medical abortion at home and in a clinic: a systematic review Experiences of women who travel for abortion: A mixed methods systematic review At-home telemedicine for medical abortion in Australia: A qualitative study of patient experiences and recommendations. BMJ Sexual and Reproductive Health Women's experiences of the final stage of early medical abortion at home: Results of a pilot survey Barriers to accessing termination of pregnancy ina remote and rural setting: a qualitative study Barriers to accessing abortion services and perspectives on using mifepristone and misoprostol at home in Great Britain Abigail All rights reserved. No reuse allowed without permission. perpetuity preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in Women's experiences of self-administration of misoprostol at home as part of early medical abortion: A qualitative evaluation Self-management of first trimester medical termination of pregnancy: a qualitative study of women's experiences National Institute for Health and Care Excellence Experiences of women who travel for abortion: A mixed methods systematic review Abortion Worldwide 2017: Uneven Progress and Unequal Access Early medical abortion by telemedicine in the United Kingdom: a costing analysis World Health Organization. Medical management of abortion Chief Medical Officer Directorate. Abortion -Improvement to existing servicesapproval for misoprostol to be taken at home Abortion statistics by clinic Ministry of Housing Communities & Local Government. IMD Definition of disability under the Equality Act Information for healthcare professionals Coronavirus (COVID-19) infection and abortion care The Abortion Act 1967 -Approval of a Class of Places Women's experiences of self-administration of misoprostol at home as part of early medical abortion: a qualitative evaluation If we can do it for misoprostol, why not for mifepristone? The case for taking mifepristone out of the office in medical abortion Acceptability of home use of mifepristone for medical abortion Comment on DHSC Abortion Statistics: Telemedical abortion service results in significant drop in gestation at which women can access care -protecting their health during the pandemic Should COVIDspecific arrangements for abortion continue? The views of women experiencing abortion in Britain during the pandemic. Preprint. medRxiv The Preprint Server for Health Sciences We would like to thank BPAS for providing us with their clinical data. Data reported in this analysis is not available as it is subject to an ethical permission restricted to the authors of the manuscript. Authors' note on terminology